| Rajbir Sidhu, MD | |
|
10666 N Torrey Pines Rd, La Jolla, CA 92037-1027 | |
| (858) 554-7909 | |
| Not Available |
| Full Name | Rajbir Sidhu |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 9 Years |
| Location | 10666 N Torrey Pines Rd, La Jolla, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164818118 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanford Health Care | Stanford, CA | Hospital |
| Eden Medical Center | Castro valley, CA | Hospital |
| Alta Bates Summit Medical Center | Oakland, CA | Hospital |
| Alta Bates Summit Medical Center - Alta Bates Camp | Berkeley, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stanford Health Care | 6709797491 | 2572 |
| Sutter Bay Medical Foundation | 4284538778 | 2941 |
| University Healthcare Alliance | 6305748799 | 346 |
News Archive
Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).
Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.
The U.S. Food and Drug Administration today approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus. This assay is approved for use as an aid in the diagnosis of HIV-1/HIV-2 infection in adults including pregnant women. It is also the first assay for use as an aid in the diagnosis of HIV-1/HIV-2 infection in children as young as two years old.
The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc, applauded the federal government's decision last week to maintain the current, single reimbursement code for negative pressure wound therapy (NPWT) devices.
Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.
› Verified 6 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).
Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.
The U.S. Food and Drug Administration today approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus. This assay is approved for use as an aid in the diagnosis of HIV-1/HIV-2 infection in adults including pregnant women. It is also the first assay for use as an aid in the diagnosis of HIV-1/HIV-2 infection in children as young as two years old.
The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc, applauded the federal government's decision last week to maintain the current, single reimbursement code for negative pressure wound therapy (NPWT) devices.
Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.
› Verified 6 days ago
| Entity Name | Sutter Bay Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013950807 PECOS PAC ID: 4284538778 Enrollment ID: O20031125000909 |
News Archive
Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).
Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.
The U.S. Food and Drug Administration today approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus. This assay is approved for use as an aid in the diagnosis of HIV-1/HIV-2 infection in adults including pregnant women. It is also the first assay for use as an aid in the diagnosis of HIV-1/HIV-2 infection in children as young as two years old.
The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc, applauded the federal government's decision last week to maintain the current, single reimbursement code for negative pressure wound therapy (NPWT) devices.
Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.
› Verified 6 days ago
| Entity Name | University Healthcare Alliance |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760531198 PECOS PAC ID: 6305748799 Enrollment ID: O20040126000292 |
News Archive
Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).
Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.
The U.S. Food and Drug Administration today approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus. This assay is approved for use as an aid in the diagnosis of HIV-1/HIV-2 infection in adults including pregnant women. It is also the first assay for use as an aid in the diagnosis of HIV-1/HIV-2 infection in children as young as two years old.
The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc, applauded the federal government's decision last week to maintain the current, single reimbursement code for negative pressure wound therapy (NPWT) devices.
Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rajbir Sidhu, MD 10790 Rancho Bernardo Rd, San Diego, CA 92127-5705 Ph: (858) 554-7909 | Rajbir Sidhu, MD 10666 N Torrey Pines Rd, La Jolla, CA 92037-1027 Ph: (858) 554-7909 |
News Archive
Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).
Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.
The U.S. Food and Drug Administration today approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus. This assay is approved for use as an aid in the diagnosis of HIV-1/HIV-2 infection in adults including pregnant women. It is also the first assay for use as an aid in the diagnosis of HIV-1/HIV-2 infection in children as young as two years old.
The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc, applauded the federal government's decision last week to maintain the current, single reimbursement code for negative pressure wound therapy (NPWT) devices.
Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.
› Verified 6 days ago
Dr. Laura J. Nicholson, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-455-9100 Fax: 858-784-5933 | |
Ashkan Hayatdavoudi, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-7909 | |
Darius Leung, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10666 N. Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-3200 | |
Ola Jandali, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-7909 | |
Dr. Kimberly D Koppenbrink, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, Suite # 206, La Jolla, CA 92037 Phone: 858-455-9100 | |
Dr. Dan E. Dworsky, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-8374 Fax: 858-784-5933 | |
Dr. Mark C. Kyle, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10666 N Torrey Pines Rd, La Jolla, CA 92037 Phone: 858-554-6158 Fax: 858-554-6565 |